Jafron Biomedical first-half 2026 revenue falls 8.99% to RMB 1.032 billion; net profit down 1.99%
Jafron Biomedical disclosed its 2026 semi-annual report on August 6. In the first half of 2026, the company recorded total operating revenue of RMB 1.032 billion, down 8.99% year on year; net profit attributable to shareholders of the listed company was RMB 382 million, down 1.99%; and basic earnings per share came to RMB 0.49.
During the reporting period, affected by external factors such as fluctuations in industry demand and intensifying market competition, the company's overall revenue declined year on year.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is negative for Medical Consumables, with intensity 30/100 and 40% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.